Speaker illustration

Doctor Andrew Arai

National Institutes of Health, Bethesda (United States of America)

Andrew E. Arai, M.D., F.A.H.A. joined the National Heart, Lung, and Blood Institute (NHLBI) in 1993. He is Chief of the Advanced Cardiovascular Imaging Laboratory in the Institute's Division of Intramural Research. Dr. Arai is also Past President of the Society for Cardiovascular Magnetic Resonance. Dr. Arai’s research focuses on coronary artery disease, heart attack, and other diseases that affect the heart or blood vessels. His expertise is in the use of cardiac magnetic resonance imaging (CMR) to evaluate patients.

Gadobutrol enhanced CMR to detect significant coronary artery disease defined by quantitative coronary angiography. Results from two blinded phase III clinical trials

Event: ESC CONGRESS 2019

Topic: Stress Cardiac Magnetic Resonance (CMR)

Session: Innovations in CMR imaging of coronary artery disease

Thumbnail

Role of CMR for personalised risk stratification in STEMI.

Event: EuroCMR 2019

Topic: Late Gadolinium Enhancement

Session: Cardiovascular Magnetic Resonance in acute coronary syndromes: luxury or do we need it?

Thumbnail

Fully quantitative myocardial perfusion - A clinical reality.

Event: EuroCMR 2019

Topic: Cardiac Magnetic Resonance (CMR)

Session: The next level of mapping - Quantitative perfusion and electrophysiology

Thumbnail

Anatomy of coronary stenosis is better than function to predict outcomes: CON.

Event: EuroCMR 2019

Topic: Stress Cardiac Magnetic Resonance (CMR)

Session: Pros/cons in ischaemic heart diseases

Thumbnail

Magnetic resonance imaging in LV hypertrophy: how to interpret correctly.

Event: ESC Congress 2018

Topic: IMAGING

Session: Image Interpretation with the Masters: Left ventricular hypertrophy

Thumbnail

State of the Art: CMR of myocardial perfusion and scar

Event: ESC CONGRESS 2017

Topic: Cardiovascular Magnetic Resonance (CMR)

Session: Prognostic value of Cardiac Magnetic Resonance (CMR)

Thumbnail

This platform is supported by

logo Novo Nordisk